+4 year(s) experience
Rajan Writes For
By Rajan Sharma 21 Sep 2015
The sodium-glucose cotransporter-2 (SGLT-2) inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) is expected to experience a significant increase in uptake in the type 2 diabetes market after the presentation of its much-anticipated cardiovascular (CV) outcomes data at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden.
By Rajan Sharma 19 Sep 2014
Eli Lilly’s Trulicity (dulaglutide) has, this week, been approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Our forecast
Topics Drug approval
By Rajan Sharma 04 Sep 2014
The European Society of Cardiology’s 2014 Annual Congress was described as having the ‘strongest scientific program yet’ by Professor Keith Fox.